Left Ventricular Mass Progression despite Stable Blood Pressure and Kidney Function in Stage 3 Chronic Kidney Disease

Michael E. Seifert\textsuperscript{a,b,e}  Lisa de las Fuentes\textsuperscript{c,f}  Charles Ginsberg\textsuperscript{f}  
Marcos Rothstein\textsuperscript{d,f}  Dennis J. Dietzen\textsuperscript{e}  Steven C. Cheng\textsuperscript{d,f}  Will Ross\textsuperscript{d,f}  
David Windus\textsuperscript{d,f}  Victor G. Dávila-Román\textsuperscript{c,f}  Keith A. Hruska\textsuperscript{b,e}  

\textsuperscript{a}Division of Pediatric Nephrology, Southern Illinois University, Springfield, Ill.  \textsuperscript{b}Division of Pediatric Nephrology, Cardiovascular Imaging and Clinical Research Core Laboratory, Cardiovascular Division, \textsuperscript{c}Renal Division, and Departments of \textsuperscript{d}Pediatrics and \textsuperscript{e}Medicine, Washington University, St. Louis, Mo., USA

Key Words  
Cardiovascular biomarkers · Chronic kidney disease · Ventricular hypertrophy

Abstract  
Background/Aims: Progressive chronic kidney disease (CKD) is associated with worsening cardiovascular (CV) risk not explained by traditional risk factors. Left ventricular (LV) hypertrophy (LVH) is an important CV risk factor, but its progression has not been documented in early CKD. We explored whether progression of LVH in early CKD would occur despite stable kidney function. Methods: We conducted a post hoc analysis of a 12-month study of lanthanum carbonate in stage 3 CKD, which included longitudinal assessments of CV biomarkers. Primary outcome for the analysis was the change in LV mass (LVM) indexed to height in meters\textsuperscript{2.7} (LVM/Ht\textsuperscript{2.7}). Secondary outcomes were changes in blood pressure (BP), pulse-wave velocity, LV systolic/diastolic function, fibroblast growth factor 23 (FGF23), klotho, and estimated glomerular filtration rate (eGFR). Results: Thirty-one of 38 original subjects had sufficient data for analysis. LVM/Ht\textsuperscript{2.7} increased (47 ± 13 vs. 53 ± 13 g/m\textsuperscript{2.7}, p = 0.006) over 12 months despite stable BP, stable eGFR and normal LV systolic function. Vascular stiffness and LV diastolic dysfunction persisted throughout the study. Klotho levels decreased (748 ± 289 to 536 ± 410 pg/ml, p = 0.03) but were unrelated to changes in LVM/Ht\textsuperscript{2.7}. The change in FGF23/klotho ratio was strongly correlated with changes in LVM/Ht\textsuperscript{2.7} (r\textsuperscript{2} = 0.582, p = 0.03). Conclusion: Subjects with stage 3 CKD exhibited increasing LVM, persistent LV diastolic dysfunction and vascular stiffness despite stable kidney function, BP and LV systolic function. Abnormal FGF23 signaling due to reduced klotho expression may be associated with increasing LVM. These findings deserve further evaluation in a larger population given the adverse prognostic value of these CV biomarkers.

Introduction  
Chronic kidney disease (CKD) is associated with increased cardiovascular (CV) risk compared with the general population [1–3]. Traditional CV risk factors such as age, sex, smoking, hypertension, cholesterol, and diabetes

© 2014 S. Karger AG, Basel
LV Mass Progression in Stable Stage 3 CKD

Subjects and Methods

Subjects

The original study protocol and post hoc analysis were both approved by the Human Research Protection Office at Washington University in St. Louis. Inclusion criteria, exclusion criteria and methods for stratification and randomization were published previously. Specifically relevant to the post hoc analysis, a history of prior or current congestive heart failure and severe hypertension were each exclusion criteria in the original study [17]. Briefly, 38 subjects with stage 3 CKD were stratified for age, gender, race and diabetes status, and then randomized into 2 groups allocated 1:1 to receive either LaCO₃ or a matching placebo with meals 3 times daily for 12 months. The primary end point of the original study was the change in serum phosphorus. Secondary end points included the change in mean carotid-femoral PWV, 24-hour urine phosphorus, tubular reabsorption of phosphorus, vascular calcification score, carotid artery intima-media thickness, LVM/Ht².⁷, LV ejection fraction (LVEF), plasma fibroblast growth factor 23 (FGF23), plasma Dickkopf-related protein 1 (DKK1) and plasma sclerostin. LaCO₃ and placebo groups were analyzed as a single cohort in this post hoc analysis since no differences in outcomes were detected during the original study.

CV Evaluations

CV assessments were performed at baseline and 12 months. PWV was determined by use of applanation tonometry of the carotid and femoral arteries (SphygmoCor, AtCor Medical, Australia) as previously described and validated [17–22]. The applanation tonometry measurements were performed by a research technician who was blinded to clinical data, echocardiographic results and treatment group. Vascular stiffness was defined as a mean PWV greater than the 50th percentile for age (9.8 m/s) using data from The Reference Values for Arterial Stiffness’ Collaboration [23].

Two-dimensional (2D) and M-mode echocardiograms were performed as described previously [17]. LVEF was determined by 2D echocardiography using the modified Simpson’s method of disks; LVM was measured by the 2D-guided M-mode-derived cubed method and indexed to both body surface area (LVM/BSA) and height in meters raised to the power of 2.7 (LVM/Ht².⁷) [24]. Although LVM/BSA is commonly used in clinical trials, it underestimates the degree of LV hypertrophy (LVH) in overweight and obese individuals. LVM/Ht².⁷ enhances the ability to detect LVH in this setting [24–26]. Subjects were considered to have LVH if the LVM/Ht².⁷ was >51 g/m².⁷ [24]. Diastolic function metrics were obtained using pulsed-wave Doppler and included early peak mitral inflow velocity (E), late peak mitral inflow velocity (A), the E/A ratio, and left atrial volume (LAV) [24, 27]. Additional diastolic function metrics were obtained using pulsed-wave tissue Doppler imaging and included early diastolic lateral annular velocity (lateral e’), and the ratio of E to lateral e’ (lateral E/e’ ratio), which provides an estimate of left atrial pressure (LAP) [27]. Normal reference values for these metrics are as follows: LAV <34 ml/m², lateral e’ >10 cm/s, lateral E/e’ ratio <8 (also normal between 9–12 if normal LAV), E/A ratio 1–2 (along with normal LAP and normal lateral e’). Subjects were considered to have diastolic dysfunction if either of the following patterns were detected by echocardiography: (1) impaired myocardial relaxation: E/A <0.8, lateral e’ <10 cm/s, lateral E/e’ <8, LAV >34 ml/m², and/or (2) increased LAP: lateral E/e’ >12 with LAV >34 ml/m². The classification scheme for diastolic dysfunction was drawn from a recently published guideline by the American Society of Echocardiography [27]. All measurements were performed in accordance to published guidelines and represent the average of three consecutive cardiac cycles obtained by a single observer blinded to all clinical parameters and treatment group.
Plasma FGF23 and Soluble Klotho Levels

Blood samples were obtained from each subject at the baseline visit and after 12 months of treatment. Plasma levels of FGF23 were measured in duplicate using a commercially available ELISA kit as previously described [17]. Soluble klotho levels were measured in duplicate using a commercially available ELISA kit according to the manufacturer’s instructions (Immuno-Biological Laboratories, Japan).

Outcome Definitions

The primary outcome was the change in LVM/Ht^2.7 (g/m^2.7) from baseline to month 12. Secondary outcomes included changes in the nonindexed LVM (g) and LVM indexed to BSA [LVM/BSA (g/m^2)], systolic blood pressure (SBP), diastolic blood pressure (DBP), carotid-femoral PWV, LVEF, E velocity, A velocity, E/A ratio, lateral e’ velocity, lateral E/e’ ratio, plasma FGF23, plasma soluble klotho, FGF23/klotho ratio and eGFR (calculated using the Modification of Diet in Renal Disease Study Equation) [28] from baseline to month 12.

Statistical Analysis

Statistical analysis was performed by a statistician who remained blinded to the identity of the subjects and their original study groups (J.M.). The data were analyzed using the software package SAS 9.1 (Cary, N.C., USA). All outcomes were analyzed in both original treatment arms combined since there were no significant differences between groups in the original study [17]. The distribution of each outcome variable was evaluated for normality using Kolmogorov-Smirnov Z test. Signed-rank test (non-normally distributed data) and paired t test (normally distributed data) were used to test differences of continuous variables from baseline to the 12-month visit. Bivariate correlations involving normally distributed data were used to test differences of continuous variables from baseline to the 12-month visit. Bivariate correlations involving normally distributed variables were performed using Pearson’s correlation. Independent categorical variables were compared using the χ^2 test; paired categorical variables were compared using McNemar’s test. Normally distributed data are presented as mean ± standard deviation. Non-normally distributed data are presented as median (range). All tests were two tailed; statistical significance was considered at p < 0.05.

Results

Baseline Demographics

Of the 38 subjects from the original cohort, 31 had complete demographic, biochemical, and CV data at the baseline and 12-month visit and were included in the post hoc analysis. Subjects were excluded from the analysis due to either inadequate plasma remaining for measuring circulating klotho levels or incomplete data for assessment of diastolic function, which were both outcomes not analyzed in the original study. There were no significant differences in baseline demographic or clinical data in included versus excluded subjects (data not shown). The demographic data for the combined cohort are presented in table 1. At baseline, LVH was present in 10/31 (32%) and diastolic dysfunction was present in 15/31 (48%), all with impaired myocardial relaxation: 13 had normal LAP and 2 had increased LAP; table 2).

Primary Outcome of the Combined Cohort Analysis

Mean LVM/Ht^2.7 significantly increased from 47.4 ± 13.2 g/m^2.7 at baseline to 53.4 ± 12.9 g/m^2.7 at 12 months (p = 0.006; table 2, fig. 1). The proportion of subjects with LVH increased from 32% at baseline to 48% at 12 months, but this change was not statistically significant (table 2). Of the subjects without LVH at baseline, 29% developed LVH at 12 months; in contrast, only one subject with LVH at baseline demonstrated normal LVM/Ht^2.7 at 12 months. The change in LVM/Ht^2.7 from baseline to the 12-month visit was similar within the original study groups (LaCO3: 45.6 ± 13.4 to 53.2 ± 13.3 g/m^2.7, p = 0.44; placebo: 49.3 ± 13.2 to 53.6 ± 13.0 g/m^2.7, p = 0.51). The between-group comparison of the change in LVM/Ht^2.7 was not statistically significant (p = 0.36). Mean eGFR was 46 ml/min/1.73 m^2 at baseline and did not significantly change during the study, demonstrating stability of stage 3 CKD during the follow-up period (table 2).

Secondary Outcomes in the Combined Cohort Analysis

Mean nonindexed LVM significantly increased from 203 ± 79 g at baseline to 223 ± 70 g at 12 months (p = 0.02; table 2). Mean LVM/BSA also significantly increased from 100 ± 29 g/m^2 at baseline to 106 ± 27 g/m^2 at 12
Diastolic function

<table>
<thead>
<tr>
<th>Biochemical data</th>
<th>Baseline (n = 31)</th>
<th>12 months (n = 31)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td>31 ± 5</td>
<td>32 ± 6</td>
<td>0.16</td>
</tr>
<tr>
<td>Serum creatinine, mg/dl</td>
<td>1.7 ± 0.3</td>
<td>1.7 ± 0.4</td>
<td>0.80</td>
</tr>
<tr>
<td>eGFR, ml/min/1.73 m²</td>
<td>46 ± 12</td>
<td>47 ± 15</td>
<td>0.95</td>
</tr>
<tr>
<td>Serum calcium, mg/dl</td>
<td>9.2 ± 0.3</td>
<td>9.5 ± 0.4</td>
<td>0.70</td>
</tr>
<tr>
<td>Serum phosphorus, mg/dl</td>
<td>3.4 ± 0.5</td>
<td>3.2 ± 0.5</td>
<td>0.80</td>
</tr>
<tr>
<td>TRP, %</td>
<td>77 ± 10</td>
<td>73 ± 10</td>
<td>0.45</td>
</tr>
<tr>
<td>Intact PTH, pg/ml</td>
<td>67 (24–201)</td>
<td>71 (33–367)</td>
<td>0.95</td>
</tr>
<tr>
<td>FGF23, pg/ml</td>
<td>58 (24–201)</td>
<td>55 (33–367)</td>
<td>0.95</td>
</tr>
<tr>
<td>Soluble klotho, pg/ml</td>
<td>748 ± 289</td>
<td>536 ± 410</td>
<td>0.03</td>
</tr>
<tr>
<td>FGF23/klotho ratio</td>
<td>0.09 ± 0.07</td>
<td>0.26 ± 0.25</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Cardiovascular data

<table>
<thead>
<tr>
<th>Cardiovascular data</th>
<th>Baseline (n = 31)</th>
<th>12 months (n = 31)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP, mm Hg</td>
<td>131 ± 14</td>
<td>130 ± 12</td>
<td>0.69</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td>77 ± 10</td>
<td>71 ± 8</td>
<td>0.01</td>
</tr>
<tr>
<td>Heart rate, beats per min</td>
<td>70 ± 10</td>
<td>69 ± 10</td>
<td>0.25</td>
</tr>
<tr>
<td>LVM, g</td>
<td>203 ± 79</td>
<td>223 ± 70</td>
<td>0.02</td>
</tr>
<tr>
<td>LVM, g/m²</td>
<td>100 ± 29</td>
<td>106 ± 27</td>
<td>0.03</td>
</tr>
<tr>
<td>LVM, g/m²²</td>
<td>47 ± 13</td>
<td>53 ± 13</td>
<td>0.006</td>
</tr>
<tr>
<td>LVH</td>
<td>10 (32)</td>
<td>15 (48)</td>
<td>0.33</td>
</tr>
<tr>
<td>LVEF, %</td>
<td>62 ± 10</td>
<td>66 ± 9</td>
<td>0.04</td>
</tr>
<tr>
<td>PWV, m/s</td>
<td>10.7 ± 1.8</td>
<td>10.1 ± 2.1</td>
<td>0.08</td>
</tr>
</tbody>
</table>

Data are presented as mean ± standard deviation, median (range), or number (%). See the 'Methods' section for normal reference values for the cardiovascular data and diastolic function variables. FGF23 is the only non-normally distributed biochemical variable and is presented as median (range). TRP = Tubular reabsorption of phosphorus; PTH = parathyroid hormone.

*Statistically significant difference in means between the baseline and 12-month visit using paired t-test.

months (p = 0.03; table 2). SBP remained stable during the study, but a small yet statistically significant decrease in DBP occurred over 12 months (table 2). We observed increased PWV, reflecting vascular stiffness at the baseline visit and at 12 months (table 2), with mean PWV greater than the 50th percentile for age (9.8 m/s) using data from The Reference Values for Arterial Stiffness’ Collaboration [23]. LVEF remained normal at >60% throughout the study, with a small but statistically significant increase from baseline to the 12-month visit (table 2).

Diastolic dysfunction was present at baseline and persisted over 12 months in many subjects, although there were no significant changes during the study (table 2). Specifically, the E velocity (median: 0.57–0.58 cm/s), A velocity (median: 0.69–0.71 cm/s), E/A ratio (median: 0.78–0.80), lateral e’ (median: 8–10 cm/s), lateral E/e’ ratio (median: 6.2–6.3), and LAV (median: 51–53 ml/m²) remained unchanged, all consistent with mild diastolic dysfunction [27] (table 2).
klotho ratio increased significantly over 12 months (0.09 ± 0.07 to 0.26 ± 0.25, p = 0.01; table 2). Of the secondary outcomes, only the change in FGF23/klotho ratio was significantly associated with the change in LVM/Ht 2.7 over 12 months (Pearson’s r² = 0.582, p = 0.03; fig. 3).

Discussion

In this post hoc analysis, we identified a significant increase in LVM/Ht 2.7 over a 12-month follow-up period in 31 adults with stage 3 CKD, despite stable BP, stable kidney function and normal LV systolic function. This increase remained significant across other definitions of LVM, including nonindexed LVM (g) and LVM indexed to BSA (g/m²). Given that approximately 10% of the general population has stage 3 CKD, there is a pressing need to identify biomarkers associated with poor CV outcomes. While it has been previously shown that biomarkers of CV risk (such as LVM) progressively worsen in patients with stage 5 CKD on dialysis, to our knowledge this is the first study to demonstrate progression of LVM (a biomarker that portends adverse CV risk) in an otherwise stable stage 3 CKD population.

We compared our findings with those of a recent study published by Chue et al. [29] that followed 109 subjects with stage 3 CKD in a 40-week placebo-controlled study using sevelamer carbonate. In their study, LVM (non-indexed and indexed to BSA) did not significantly increase in the sevelamer or placebo group over 40 weeks. An important difference between our study and that of Chue et al. [29] is their use of cardiac MRI rather than echocardiography to measure LVM, which precludes a direct comparison of primary outcomes between our two studies. Our two cohorts were similar in age, gender and eGFR, although our cohort had more vascular stiffness, more diastolic dysfunction, and a slightly longer follow-up period (52 vs. 40 weeks). Importantly, our cohort had lower baseline levels of circulating klotho that declined significantly over 12 months, versus higher baseline klotho levels that remained stable in Chue et al. [29] (using an identical ELISA kit). The decline in klotho levels in our cohort may reflect a decrease in true GFR and subclinical progression of CKD during the study that was not detected using the Modification of Diet in Renal Disease-derived eGFR, as suggested by recent studies of klotho levels as a highly sensitive biomarker of kidney injury in early CKD [30–33].

Although we detected a significant increase in LVM, this was not associated with changes in other biomarkers that have been associated with worsening CV risk such as SBP, DBP, LV systolic function, LV diastolic function, or PWV. However, it is feasible that persistently elevated PWV, a biomarker of vascular stiffness, contributed to cardiac remodeling and increasing LVM as was seen in the Multiethnic Study of Atherosclerosis [34]. Moreover,
we observed persistent, mild diastolic dysfunction over 12 months in stage 3 CKD, which has been previously reported as a correlate of increasing LVM and a strong predictor of mortality in stage 4–5 CKD [35, 36].

To our surprise and in contrast to recent animal and human studies, we did not find an association between plasma FGF23 levels and the change in LVM/Ht$^{2.7}$ [37, 38]. However, we demonstrated a significant decline in circulating klotho levels over 12 months that was not associated with a change in LVM/Ht$^{2.7}$. We suspect that the decline in circulating klotho levels reflects a loss of membrane-bound klotho from kidney tubules, as was demonstrated in a recent study by Sakam et al. [39] in patients with CKD. The loss of membrane-bound klotho should impair canonical FGF23 signaling in the kidney and CV system since klotho is the required coreceptor for FGF23/FGF receptor (FGFR) interactions [40, 41]. However, FGF23/FGFR signaling has been demonstrated in the kidney and CV system of klotho-deficient mice [30, 37]. In a seminal paper by Faul et al. [37], FGF23/FGFR signaling stimulated LVH in a dose-responsive pattern in klotho-haploinsufficient and klotho-knockout mouse models of CKD. However, in these animal models, lower expression of klotho was accompanied by higher plasma levels of FGF23, which were not seen in our cohort. In Faul et al. [37], klotho-independent FGF23/FGFR signaling was shown to induce a hypertrophic phenotype in isolated cardiac myocytes but was not tested in other resident cells playing an important role in LVH such as fibroblasts or myofibroblasts. The mechanism of klotho-independent FGF23/FGFR signaling in CKD is unknown, but one potential explanation is the promiscuous binding of FGF23 to FGFR in cardiac myocytes that is further enhanced by reduced klotho expression in the kidney and parathyroid glands [37]. A similar paradigm has been proposed by Hu et al. [30], where a loss of renal klotho and an accompanying decrease in soluble klotho levels stimulated vascular calcification in animal models of CKD. Although highly speculative, our observation that the plasma FGF23/klotho ratio increased significantly over 12 months and was associated with the change in LVM/Ht$^{2.7}$ could reflect a similar state of klotho-independent FGF23/FGFR signaling at the level of the myocardium in stage 3 CKD. As in the animal models of CKD in Faul et al. [37], this may have contributed to progression of LVM by activating hypertrophic gene programs in cardiac myocytes.

This study has several limitations inherent to post hoc analyses, the most important of which is the small sample size that limits our ability to draw inferences about the primary outcome. We computed our achieved power for detecting a difference in LVM g/m$^{2.7}$ from baseline to 12 months. Using the observed mean difference of 6 g/m$^{2.7}$ and standard deviation of 13 g/m$^{2.7}$ at each time point, the achieved power in our post hoc analysis was 77% with a two-tailed alpha of 0.05. Thus, despite the small size of our cohort, we had modest power to detect the observed small but significant change in LVM g/m$^{2.7}$. Another limitation is the lack of available plasma samples to generate data in other biomarkers of progression of LVM and heart failure in patients with CKD, such as galectin-3, ST-2, troponin I, and BNP [42]. Exhaustion of the original samples precluded several subjects from inclusion in the post hoc analysis. These biomarkers should be included in future prospective studies of the progression of LVM in CKD.

In conclusion, subjects with CKD stage 3 exhibited a progressive increase in LVM with persistent LV diastolic dysfunction and vascular stiffness over 12 months despite stable kidney function, BP and normal LV systolic function. The change in FGF23/klotho ratio was associated with increasing LVM, which may reflect klotho-independent FGF23 signaling in cardiac myocytes that has been associated with LVH in animal models of CKD. These findings deserve further evaluation in a larger population given the adverse prognostic value of progression of these CV biomarkers.

Acknowledgments

The authors are grateful to Jingnan Mao for her assistance as a statistician. The LaCO 3 and matched placebo in the original study were provided by Shire US Pharmaceuticals Inc. The study was funded by Shire US Pharmaceuticals Inc., and by NIH grants DK 070790 (K.A.H.), KL2 RR024994 and UL1 RR024992 (M.E.S. and Washington University), and L40 DK099748-01 (M.E.S.).

Disclosure Statement

K.A.H. has been a consultant for or the recipient of research funding from Shire, Genzyme and Fresenius.

References


